← Back to Clinical Trials
Recruiting NCT06871293

NCT06871293 Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06871293
Status Recruiting
Phase
Sponsor Fundación Cardioinfantil Instituto de Cardiología
Condition Long COVID-19 Syndrome
Study Type INTERVENTIONAL
Enrollment 374 participants
Start Date 2025-10-30
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Functional and cognitive rehabilitation strategyEvidence-Based Informational Support

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 374 participants in total. It began in 2025-10-30 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression in adults with chronic non-communicable diseases (NCDs) and Long Covid-19. Researchers will compare a structured rehabilitation program to informational support through evidence-based messages to determine if rehabilitation leads to better functional and cognitive outcomes in patients with Long Covid-19. Participants will be randomly assigned to one of two groups: 1. Functional and cognitive rehabilitation: Attending weekly in-person sessions for 8 weeks, including supervised physical and cognitive exercises. 2. Informational support: Receiving weekly evidence-based educational messages for 8 weeks. Participants will undergo assessments at baseline, post-intervention, and six months later, including a six-minute walk test, handgrip strength measurement, and questionnaires on disability, anxiety, depression, fatigue, dyspnea, cognitive function, and quality of life.

Eligibility Criteria

Inclusion Criteria: * Covid-19 confirmed. * History of arterial hypertension or diabetes mellitus before entering the institutional registries of the FCI-IC or HOMIL, institutional registries of the FCI-IC or HOMIL or before having the diagnosis of SARSCoV-2 infection. * Persistence of two or more concurrent symptoms, related to Covid-19 prologue, for at least 4 weeks (persistent, intermittent, or intermittent). * At least one of these symptoms must have an impact on activities of daily living. They can be physical (fatigue, dyspnea, myalgias, arthralgias) or neuropsychiatric (cognitive, sleep and emotional alterations). * Symptoms unexplained by underlying disease or other condition concomitant with SARS-CoV-2 infection. SARS-CoV-2 infection (determined by prior medical history review and participant interview). participant interview). \- Ability to read and attend functional and cognitive rehabilitation sessions or to receive the with evidence-based informational messages. Exclusion Criteria: * Age \>80 years. * Severely advanced baseline comorbidities prior to SARS-CoV-2 infection. * Presence of chronic respiratory disease (partial or permanent supplemental oxygen use), cardiac failure (LVEF\<40%) or advanced renal disease (GFR\<30%). heart failure (LVEF\<40%) or advanced renal disease (GFR\<30). * Two hospitalizations in the year prior to admission to the institutional registries of the FCI-IC and the HOMIL for the patient's underlying disease. * Dependence on a caregiver. * Orthopedic or cardiopulmonary problems that contraindicate the performance of aerobic exercise. * Neuropsychiatric or cognitive limitations that limit understanding or following commands and performing attention exercises.

Contact & Investigator

Central Contact

Karen J Moreno, PT MSc

✉ kmoreno@lacardio.org

📞 +6016672727

Frequently Asked Questions

Who can join the NCT06871293 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Long COVID-19 Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06871293 currently recruiting?

Yes, NCT06871293 is actively recruiting participants. Contact the research team at kmoreno@lacardio.org for enrollment information.

Where is the NCT06871293 trial being conducted?

This trial is being conducted at Bogotá, Colombia.

Who is sponsoring the NCT06871293 clinical trial?

NCT06871293 is sponsored by Fundación Cardioinfantil Instituto de Cardiología. The trial plans to enroll 374 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology